Taiwan Bio debuts its cell therapy platforms and strives to start another clinical trial next year for a new drug to treat critical limb ischemia. September 21, 2022 Media coverage Read More... 21 September
Taiwan Bio has been listed on the Emerging Stock Board (ESB). With its dual-track strategy, Taiwan Bio is optimistic about the outlook September 7, 2022 Media coverage Read More... 7 September
